{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:21Z","timestamp":1791228681372,"version":"4.1.0"},"reference-count":78,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2015,7,4]]},"DOI":"10.1586\/17474086.2015.1047759","type":"journal-article","created":{"date-parts":[[2015,6,20]],"date-time":"2015-06-20T01:39:35Z","timestamp":1434764375000},"page":"493-504","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Prognosis and outcome of stem cell transplantation for mantle cell lymphoma"],"prefix":"10.1586","volume":"8","author":[{"given":"Morgane","family":"Cheminant","sequence":"first","affiliation":[{"name":"Hematology Department, Necker Hospital, Paris Descartes \u2013 Sorbonne Paris Cit\u00e9 University, INSERM U1163 CNRS ERL8654, Imagine Institute,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[{"name":"BMT Unit, University Hospital Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Hematology Department, Institut Gustave Roussy,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital Nantes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[{"name":"Hematology Department, Necker Hospital, Paris Descartes \u2013 Sorbonne Paris Cit\u00e9 University, INSERM U1163 CNRS ERL8654, Imagine Institute,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[{"name":"Hematology Department, Necker Hospital, Paris Descartes \u2013 Sorbonne Paris Cit\u00e9 University, INSERM U1163 CNRS ERL8654, Imagine Institute,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Hematology Department, Necker Hospital, Paris Descartes \u2013 Sorbonne Paris Cit\u00e9 University, INSERM U1163 CNRS ERL8654, Imagine Institute,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,6,19]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00366-5"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Hoster E Rosenwald A Berger F et al. Tumor cell proliferation (Ki-67 Index) overcomes cytology and growth pattern as prognostic factor in mantle-cell lymphoma \u2013 results from randomized trials of the European MCL Network. Abstract 2977. Presented at: ASH Annual Meeting. 6-9 December 2014 Atlanta GA USA","DOI":"10.1182\/blood.V124.21.2977.2977"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Rule S Smith P Johnson PW et al. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) Trial. Abstract 440. Presented at: ASH Annual Meeting. 8-11 December 2012 Atlanta GA USA","DOI":"10.1182\/blood.V118.21.440.440"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2476"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2845"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1860-8"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.568"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"issue":"3","key":"e_1_3_3_25_1","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"De Guibert S","year":"2006","unstructured":"De Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006;91(3):425-6","journal-title":"Haematologica"},{"issue":"10","key":"e_1_3_3_26_1","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefr\u00e8re F","year":"2004","unstructured":"Lefr\u00e8re F, Delmer A, Levy V, et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004;89(10):1275-6","journal-title":"Haematologica"},{"issue":"11","key":"e_1_3_3_27_1","first-page":"1580","article-title":"High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma","volume":"90","author":"Vigouroux S","year":"2005","unstructured":"Vigouroux S, Gaillard F, Moreau P, et al. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005;90(11):1580-2","journal-title":"Haematologica"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Rubio MT Boumendil A Luan JJ et al. Is there still a place for total body irradiation in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study from the Lymphoma Working Party of the EBMT. 2011; Abstract 688. Presented at: Lugano Annual Meeting 15-18 June 2011 Switzerland","DOI":"10.1182\/blood.V116.21.688.688"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.223"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.882506"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.10.007"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22126"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Le Gouill S Thieblemont C Oberic L et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective LyMa trial a Lysa study. 2014; Abstract 146. Presented at: ASH Annual Meeting. 6-9 December 2014 Atlanta GA USA","DOI":"10.1182\/blood.V124.21.146.146"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-11-0107"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Hermine O Hoster E Walewski J et al. Alternating courses of 3xCHOP and 3xDHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European mantle cell lymphoma Network. Hematol Oncol. 2012; Abstract 151. Presented at: ASH Annual Meeting. 8-11 December 2012 Atlanta GA USA","DOI":"10.1182\/blood.V120.21.151.151"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu097"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391474"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370122"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.4.1421"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184200"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2087-z"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.04.006"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds054"},{"issue":"4","key":"e_1_3_3_51_1","first-page":"418","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand P","year":"2008","unstructured":"Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. J Am Soc 2008;14(4):418-25","journal-title":"J Am Soc"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi107"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7865"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8157"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404822"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3523"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088997"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8865"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1864"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.171"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07329.x"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400580"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12854"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3116"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_3_3_76_1","doi-asserted-by":"crossref","unstructured":"Franco C Brendan R Lixia P et al. Randomized phase 3 study of rituximab cyclophosphamide doxorubicin and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients ineligible for bone marrow transplantation. 2014; Abstract 8500. Presented at: ASCO Annual Meeting. 30 May-3 June 2014 Chicago USA","DOI":"10.1200\/jco.2014.32.15_suppl.8500"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.907891"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"issue":"4","key":"e_1_3_3_82_1","first-page":"625","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani M","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. J Am Soc 2013;19(4):625-31","journal-title":"J Am Soc"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474086.2015.1047759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:28:50Z","timestamp":1772731730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474086.2015.1047759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7,4]]}},"alternative-id":["10.1586\/17474086.2015.1047759"],"URL":"https:\/\/doi.org\/10.1586\/17474086.2015.1047759","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}